Ciaran P Kelly

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Clostridium difficile outbreaks: prevention and treatment strategies
    Fernando J Martinez
    Division of Gastroenterology, Department of Medicine, University of Miami, Miller School of Medicine, Miami, FL, USA
    Risk Manag Healthc Policy 5:55-64. 2012
  2. doi request reprint Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study
    C P Kelly
    Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Aliment Pharmacol Ther 37:252-62. 2013
  3. doi request reprint Can we identify patients at high risk of recurrent Clostridium difficile infection?
    C P Kelly
    Gastroenterology Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Clin Microbiol Infect 18:21-7. 2012
  4. doi request reprint Current strategies for management of initial Clostridium difficile infection
    Ciaran P Kelly
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Hosp Med 7:S5-10. 2012
  5. ncbi request reprint A 76-year-old man with recurrent Clostridium difficile-associated diarrhea: review of C. difficile infection
    Ciaran P Kelly
    Harvard Medical School, Boston, MA, USA
    JAMA 301:954-62. 2009
  6. doi request reprint The host immune response to Clostridium difficile
    Ciaran P Kelly
    Gastroenterology Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA
    J Med Microbiol 60:1070-9. 2011
  7. ncbi request reprint Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea
    Stavros Sougioultzis
    Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, 02215, USA
    Gastroenterology 128:764-70. 2005
  8. pmc Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease
    Daniel Leffler
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
    Gut 62:996-1004. 2013
  9. doi request reprint Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection
    Mary Y Hu
    Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Gastroenterology 136:1206-14. 2009
  10. ncbi request reprint Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis
    Xinhua Chen
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Biol Chem 281:24449-54. 2006

Research Grants

  1. Immune Response to Clostridium difficile
    Ciaran Kelly; Fiscal Year: 2007
  2. Immune Response to Clostridium difficile
    Ciaran Kelly; Fiscal Year: 2006
  3. Immune Response to Clostridium difficile
    Ciaran Kelly; Fiscal Year: 2005
  4. MECHANISMS OF LEUKOCYTE RECRUITMENT IN IBD
    Ciaran Kelly; Fiscal Year: 2005
  5. Immune Response to Clostridium difficile
    Ciaran Kelly; Fiscal Year: 2004
  6. MECHANISMS OF LEUKOCYTE RECRUITMENT IN IBD
    Ciaran Kelly; Fiscal Year: 2004
  7. MECHANISMS OF LEUKOCYTE RECRUITMENT IN IBD
    Ciaran Kelly; Fiscal Year: 2003
  8. MECHANISMS OF LEUKOCYTE RECRUITMENT IN IBD
    Ciaran Kelly; Fiscal Year: 2002
  9. PATHOGENIC MECHANISMS OF HELICOBACTER PYLORI GASTRITIS
    Ciaran Kelly; Fiscal Year: 2002
  10. PATHOGENIC MECHANISMS OF HELICOBACTER PYLORI GASTRITIS
    Ciaran Kelly; Fiscal Year: 2001

Detail Information

Publications65

  1. pmc Clostridium difficile outbreaks: prevention and treatment strategies
    Fernando J Martinez
    Division of Gastroenterology, Department of Medicine, University of Miami, Miller School of Medicine, Miami, FL, USA
    Risk Manag Healthc Policy 5:55-64. 2012
    ..The purpose of this article is to review the current management, treatment, infection control, and prevention strategies that are needed to combat this increasingly morbid disease...
  2. doi request reprint Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study
    C P Kelly
    Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Aliment Pharmacol Ther 37:252-62. 2013
    ..Larazotide acetate is a first-in-class oral peptide that prevents tight junction opening, and may reduce gluten uptake and associated sequelae...
  3. doi request reprint Can we identify patients at high risk of recurrent Clostridium difficile infection?
    C P Kelly
    Gastroenterology Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Clin Microbiol Infect 18:21-7. 2012
    ....
  4. doi request reprint Current strategies for management of initial Clostridium difficile infection
    Ciaran P Kelly
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Hosp Med 7:S5-10. 2012
    ..Hospitalists, as coordinators of patient care, are in an ideal position to ensure that patients receive prompt and optimal treatment based on current clinical evidence and severity of the disease...
  5. ncbi request reprint A 76-year-old man with recurrent Clostridium difficile-associated diarrhea: review of C. difficile infection
    Ciaran P Kelly
    Harvard Medical School, Boston, MA, USA
    JAMA 301:954-62. 2009
    ..Careful attention to antimicrobial stewardship and infection control practices is essential to curb this nosocomial, iatrogenic disease...
  6. doi request reprint The host immune response to Clostridium difficile
    Ciaran P Kelly
    Gastroenterology Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA
    J Med Microbiol 60:1070-9. 2011
    ..However, further work is needed in this area to guide the clinical application of new approaches to disease prevention and treatment including new antimicrobials as well as passive and active immunization...
  7. ncbi request reprint Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea
    Stavros Sougioultzis
    Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, 02215, USA
    Gastroenterology 128:764-70. 2005
    ..Our aim was to examine whether the vaccine is also well tolerated and immunogenic in patients with recurrent CDAD...
  8. pmc Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease
    Daniel Leffler
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
    Gut 62:996-1004. 2013
    ..Lack of data regarding the kinetics of responses to gluten is a limitation in clinical practice and research when GC is performed...
  9. doi request reprint Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection
    Mary Y Hu
    Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Gastroenterology 136:1206-14. 2009
    ..This study aimed to develop a prediction rule for recurrent CDI using the above derivation cohort and prospectively evaluate the performance of this rule in an independent validation cohort...
  10. ncbi request reprint Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis
    Xinhua Chen
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Biol Chem 281:24449-54. 2006
    ..This study indicates a new mechanism whereby Sb protects against intestinal inflammation and supports the hypothesis that Sb modulates host inflammatory signaling pathways to exert its beneficial effects...
  11. ncbi request reprint Celiac disease or non-celiac gluten sensitivity? An approach to clinical differential diagnosis
    Toufic A Kabbani
    1 Celiac Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA 2 Harvard School of Public Health, Boston, Massachusetts, USA
    Am J Gastroenterol 109:741-6; quiz 747. 2014
    ..Differentiating between celiac disease (CD) and non-celiac gluten sensitivity (NCGS) is important for appropriate management but is often challenging...
  12. doi request reprint Clostridium difficile--more difficult than ever
    Ciaran P Kelly
    Gastroenterology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 359:1932-40. 2008
  13. pmc A prospective study of risk factors and historical trends in metronidazole failure for Clostridium difficile infection
    Mary Y Hu
    Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Gastroenterol Hepatol 6:1354-60. 2008
    ..The aims of this study were to compare current and historical rates of metronidazole failure and to identify risk factors for metronidazole failure...
  14. pmc Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters
    Efi Kokkotou
    Division of Gastroenterology, Dana 601 East Campus, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Antimicrob Agents Chemother 52:1121-6. 2008
    ..These findings, in conjunction with the pharmacokinetic and safety profiles of rifaximin, suggest that it is an attractive candidate for clinical use for CDAD...
  15. ncbi request reprint Human antibody response to surface layer proteins in Clostridium difficile infection
    Denise Drudy
    Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    FEMS Immunol Med Microbiol 41:237-42. 2004
    ..6-376.3). Further studies which examine the specific anti-SLP antibody responses to the colonising strain are warranted to determine if immune responses to C. difficile SLPs play a role in protection from CDAD...
  16. ncbi request reprint Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea
    Lorraine Kyne
    Gerontology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Infect Control Hosp Epidemiol 23:653-9. 2002
    ..To determine the diagnostic accuracy of an index of underlying disease severity (Horn's index) in identifying patients with a high probability of having nosocomial Clostridium difficile diarrhea as a complication of antimicrobial therapy...
  17. ncbi request reprint Etiologies and predictors of diagnosis in nonresponsive celiac disease
    Daniel A Leffler
    Department of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Gastroenterol Hepatol 5:445-50. 2007
    ..The aim of this study was to determine the common etiologies of NRCD in a tertiary referral center...
  18. pmc Open conformation tissue transglutaminase testing for celiac dietary assessment
    Kumar Pallav
    The Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Dig Liver Dis 44:375-8. 2012
    ..Anti tissue-transglutaminase antibody is the mainstay of celiac disease serologic testing. Whilst it has high sensitivity in patients on an unrestricted diet, sensitivity is poor for evaluation of gluten free diet adherence...
  19. ncbi request reprint Macrophage-inflammatory protein-3alpha mediates epidermal growth factor receptor transactivation and ERK1/2 MAPK signaling in Caco-2 colonic epithelial cells via metalloproteinase-dependent release of amphiregulin
    Sarah Keates
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    J Immunol 178:8013-21. 2007
    ....
  20. ncbi request reprint A mouse model of Clostridium difficile-associated disease
    Xinhua Chen
    Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 135:1984-92. 2008
    ..The aim of this study was to establish a mouse model of antibiotic-induced C. difficile-associated disease (CDAD) that more closely resembles human disease...
  21. doi request reprint Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI)
    Brett A Leav
    MassBiologics, University of Massachusetts Medical School, Boston, MA, USA
    Vaccine 28:965-9. 2010
    ..Previous studies have demonstrated a correlation between Clostridium difficile anti-toxin A serum antibodies and protection against symptomatic disease and recurrence...
  22. ncbi request reprint Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression
    Stavros Sougioultzis
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Biochem Biophys Res Commun 343:69-76. 2006
    ..SAIF may mediate, at least in part, the beneficial effects of Saccharomyces boulardii in infectious and non-infectious human intestinal disease...
  23. pmc Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice
    Xinhua Chen
    Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Gastroenterology 137:914-23. 2009
    ..The aim of this study was to identify upstream mediators responsible for extracellular signal-regulated kinase (Erk)1/2 inactivation and to examine the effects of Sb on tumor development in Apc(Min) mice...
  24. doi request reprint Psychological correlates of gluten-free diet adherence in adults with celiac disease
    Jessica B Edwards George
    Department of Gastroenterology, Beth Israel Deaconess Medical Center BIDMC, The Celiac Center, Harvard Medical School, Northeastern University, Boston, MA02215 5491, USA
    J Clin Gastroenterol 43:301-6. 2009
    ..To determine whether personality traits and psychological characteristics are related to gluten-free diet (GFD) adherence in an adult population diagnosed with celiac disease (CD)...
  25. ncbi request reprint Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis
    Brian Hyett
    Division of Gastroenterology, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    Gastroenterology 137:445-52. 2009
    ..The aim of this study was to evaluate the prognostic value of gastric emptying studies on the morbidity associated with diabetic gastroparesis...
  26. pmc Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A
    Samer Aboudola
    Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Infect Immun 71:1608-10. 2003
    ..These findings support the feasibility of using a vaccine to protect high-risk individuals against C. difficile-associated diarrhea and colitis...
  27. ncbi request reprint Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease
    Kianoosh Katchar
    Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Gastroenterol Hepatol 5:707-13. 2007
    ..We investigated whether humoral immune deficiencies and/or specific IgG subclass responses are associated with recurrent CDAD...
  28. pmc Probiotic yeast inhibits VEGFR signaling and angiogenesis in intestinal inflammation
    Xinhua Chen
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 8:e64227. 2013
    ..The aim of this study was to determine whether Sb alters VEGFR (vascular endothelial growth factor receptor) signaling, a central regulator of angiogenesis...
  29. doi request reprint The incidence and clinical spectrum of refractory celiac disease in a north american referral center
    Bakht Roshan
    Department of Gastroenterology, Celiac Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Am J Gastroenterol 106:923-8. 2011
    ..However, disease patterns may be different in North America. The aim of this study was to explore the clinical spectrum of RCD in a North American population...
  30. ncbi request reprint Celiac sprue
    Richard J Farrell
    Gastroenterology Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 346:180-8. 2002
  31. pmc Patients with celiac disease have a lower prevalence of non-insulin-dependent diabetes mellitus and metabolic syndrome
    Toufic A Kabbani
    Celiac Center, Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Gastroenterology 144:912-917.e1. 2013
    ..We examined the prevalence of NIDDM and metabolic syndrome among adults with celiac disease, compared with matched controls...
  32. pmc Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A
    Claribel P Taylor
    Beth Israel Deaconess Medical Center, University of Massachusetts Medical School, Boston, Massachusetts, USA
    Vaccine 26:3404-9. 2008
    ..difficile toxin A are protective against symptomatic disease and recurrence. We examined the safety and pharmacokinetics (pk) of a novel neutralizing human monoclonal antibody against C. difficile toxin A (CDA1) in healthy adults...
  33. ncbi request reprint Refractory celiac disease
    Hani Abdallah
    The Celiac Center, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Curr Gastroenterol Rep 9:401-5. 2007
    ..Immunosuppressive agents and, more recently, autologous stem cell transplant have been used to treat type II RCD...
  34. pmc Celiac crisis is a rare but serious complication of celiac disease in adults
    Shailaja Jamma
    Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Gastroenterol Hepatol 8:587-90. 2010
    ..To improve awareness of this condition and to facilitate diagnosis, we reviewed cases of celiac crisis to identify presenting features, formulate diagnostic criteria, and develop treatment strategies...
  35. ncbi request reprint Helicobacter pylori induces up-regulation of the epidermal growth factor receptor in AGS gastric epithelial cells
    Sarah Keates
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Infect Dis 196:95-103. 2007
    ..The aim of the present study was to determine whether H. pylori could up-regulate the expression of the epidermal growth factor receptor (EGFR), a critical gene in the carcinogenic process...
  36. doi request reprint Multicenter study on the value of ICD-9-CM codes for case identification of celiac disease
    Pornthep Tanpowpong
    Department of Pediatrics, Massachusetts General Hospital for Children, Harvard Medical School, Boston, MA, USA
    Ann Epidemiol 23:136-42. 2013
    ..To evaluate the value of ICD-9-CM code for identifying celiac disease (CD)...
  37. ncbi request reprint Celiac sprue
    Andres Cardenas
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Semin Gastrointest Dis 13:232-44. 2002
    ..Treatment consists of life-long avoidance of dietary gluten to control symptoms and to prevent both immediate and long-term complications...
  38. doi request reprint A simple validated gluten-free diet adherence survey for adults with celiac disease
    Daniel A Leffler
    Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Gastroenterol Hepatol 7:530-6, 536.e1-2. 2009
    ..The aim of this study was to develop a valid and reliable Celiac Dietary Adherence Test (CDAT)...
  39. ncbi request reprint Multicenter study on season of birth and celiac disease: evidence for a new theoretical model of pathogenesis
    Pornthep Tanpowpong
    Division of Pediatric Gastroenterology, Hepatology and Nutrition, Massachusetts General Hospital for Children, Boston, MA 02114, USA
    J Pediatr 162:501-4. 2013
    ..To investigate whether season of birth is associated with celiac disease (CD)...
  40. pmc Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters
    Pauline M Anton
    Beth Israel Deaconess Medical Center, Division of Gastroenterology, Dana 601, 330 Brookline Ave, Boston, MA 02215, USA
    Antimicrob Agents Chemother 48:3975-9. 2004
    ..Our results indicate that once daily rifalazil may be superior to vancomycin for curative treatment of CDAD...
  41. ncbi request reprint A validated disease-specific symptom index for adults with celiac disease
    Daniel A Leffler
    Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Gastroenterol Hepatol 7:1328-34, 1334.e1-3. 2009
    ..Although the incidence of celiac disease (CD) is increasing, studies have been hampered by the lack of validated outcome measures. We sought to create a disease-specific Celiac Symptom Index (CSI) to reliably assess relevant symptoms...
  42. doi request reprint Navigating the gluten-free diet in college
    Rebecca M Panzer
    Center for Child and Adolescent Health Research and Policy, Massachusetts General Hospital for Children, Boston, MA, USA
    J Pediatr Gastroenterol Nutr 55:740-4. 2012
    ..Tools and strategies that facilitate communication between students and dining services may improve adherence...
  43. pmc Factors that influence adherence to a gluten-free diet in adults with celiac disease
    Daniel A Leffler
    Department of Gastroenterology, The Celiac Center, Dana 501, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
    Dig Dis Sci 53:1573-81. 2008
    ..The purpose of this study was to determine factors influencing gluten-free diet adherence in adults with celiac disease...
  44. pmc Helicobacter pylori moves through mucus by reducing mucin viscoelasticity
    Jonathan P Celli
    Department of Physics, Boston University, Boston, MA 02215, USA
    Proc Natl Acad Sci U S A 106:14321-6. 2009
    ..pylori does not bore its way through the mucus gel like a screw through a cork as has previously been suggested, but instead achieves motility by altering the rheological properties of its environment...
  45. pmc The Oslo definitions for coeliac disease and related terms
    Jonas F Ludvigsson
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
    Gut 62:43-52. 2013
    ..The literature suggests a lack of consensus on the use of terms related to coeliac disease (CD) and gluten...
  46. ncbi request reprint Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile
    Lorraine Kyne
    Division of Gerontology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, 02215, USA
    Clin Infect Dis 34:346-53. 2002
    ..On the basis of the findings of this study, a conservative estimate of the cost of this disease in the United States exceeds $1.1 billion per year...
  47. doi request reprint Small intestinal release mesalamine for the treatment of refractory celiac disease type I
    Shailaja Jamma
    Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Clin Gastroenterol 45:30-3. 2011
    ..The goal of this study is to evaluate the safety and efficacy of Small intestinal release mesalamine (SIRM) for symptom relief in refractory celiac disease (RCD)...
  48. ncbi request reprint Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori
    Stavros Sougioultzis
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Vaccine 21:194-201. 2002
    ..In conclusion, rectal delivery of 5 microg LT is safe and induces vigorous systemic anti-LT immune responses. Further studies are needed to determine if LT can be an effective adjuvant for rectally delivered antigens...
  49. ncbi request reprint Meta-analysis of the placebo response in ulcerative colitis
    Sagar Garud
    Department of Medicine, Beth Israel Deaconess Medical Center, 300 Deaconess Building, 1 Deaconess Road, Boston, MA 02215, USA
    Dig Dis Sci 53:875-91. 2008
    ..The placebo response rate in randomized controlled trials (RCTs) in ulcerative colitis (UC) varies from 0 to 76%. The aims of this study were to quantify the pooled placebo response rate and identify the factors affecting it...
  50. ncbi request reprint Celiac disease: epidemiology, pathogenesis, diagnosis, and nutritional management
    Detlef Schuppan
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nutr Clin Care 8:54-69. 2005
    ..Current research focuses on non-dietary therapies and treatment of refractory (diet-unresponsive) CD...
  51. pmc Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice
    Chandrabali Ghose
    Division of Infectious Diseases, Massachusetts General Hospital, Jackson 504, 55 Fruit Street, Boston, MA 02114, USA
    Infect Immun 75:2826-32. 2007
    ..Our results suggest that transcutaneous immunization with CDA toxoid may be a feasible immunization strategy against C. difficile, an important cause of morbidity and mortality against which current preventative strategies are failing...
  52. ncbi request reprint The interaction between eating disorders and celiac disease: an exploration of 10 cases
    Daniel A Leffler
    The Celiac Center, Department of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Dana, Boston, MA 02215, USA
    Eur J Gastroenterol Hepatol 19:251-5. 2007
    ..Our findings suggest that clinicians treating patients with eating disorders or celiac disease should be aware of both conditions to provide optimum care...
  53. ncbi request reprint Monitoring non-responsive patients with celiac disease
    Detlef Schuppan
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Gastrointest Endosc Clin N Am 16:593-603. 2006
    ..At present the prognosis of RCd type II or EATL is poor due to lack of effective therapies. However, treatments that effectively target the aberrant lymphocytes can be anticipated...
  54. doi request reprint The incidence and cost of unexpected hospital use after scheduled outpatient endoscopy
    Daniel A Leffler
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Arch Intern Med 170:1752-7. 2010
    ..Data on complications of gastrointestinal endoscopic procedures are limited. We evaluated prospectively the incidence and cost of hospital visits resulting from outpatient endoscopy...
  55. ncbi request reprint Update on the evaluation and diagnosis of celiac disease
    Daniel A Leffler
    Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Curr Opin Allergy Clin Immunol 6:191-6. 2006
    ..Understanding the risk factors, clinical presentations and diagnostic modalities is necessary to identify and treat patients with this commonly misdiagnosed disorder...
  56. doi request reprint Clostridium difficile infection in the inflammatory bowel disease patient
    Adam M Berg
    Section of Gastroenterology, Boston Medical Center, Boston, Massachusetts 02118 2338, USA
    Inflamm Bowel Dis 19:194-204. 2013
    ..This review will focus on the unique epidemiology of CDI in IBD patients, detail clinical disease states, and provide updated diagnostic strategies, prevention and treatment options...
  57. doi request reprint Nondietary therapies for celiac disease
    Rupa Mukherjee
    Department of Medicine, Division of Gastroenterology, The Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Gastrointest Endosc Clin N Am 22:811-31. 2012
    ..These novel strategies provide promise of alternative, adjunctive treatment options but also raise important questions regarding safety, efficacy, and monitoring of long-term treatment effect...
  58. pmc Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4
    Yvonne Junker
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Exp Med 209:2395-408. 2012
    ..These findings define cereal ATIs as novel contributors to celiac disease. Moreover, ATIs may fuel inflammation and immune reactions in other intestinal and nonintestinal immune disorders...
  59. ncbi request reprint Reflux, dyspepsia, and disorders of the foregut
    Alan C Moss
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    South Med J 100:266-72; quiz 273, 294. 2007
    ..Disorders of the foregut are an increasingly common cause of symptoms in Western populations. This review summarizes recent advances in the understanding and treatment of gastroesophageal reflux disease, dyspepsia and celiac disease...
  60. ncbi request reprint Novel therapeutic approaches for celiac disease
    Rohini R Vanga
    Celiac Center and Department of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Discov Med 17:285-93. 2014
    ..It is hoped that non-dietary therapy for celiac disease will become available in the coming years and can both reduce the burden of treatment of celiac disease and help patients whose symptoms do not respond completely to the GFD. ..
  61. ncbi request reprint Quantifying gastric Helicobacter pylori infection: a comparison of quantitative culture, urease breath testing, and histology
    Sanjeev Tummala
    Department of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Dig Dis Sci 52:396-401. 2007
    ..pylori infection. Thus, decrements in bacterial numbers during single-agent therapy cannot be measured reliably by UBT and therefore cannot be used to evaluate the potential efficacy of novel agents to treat gastric H. pylori infection...
  62. pmc Body-mass index and symptoms of gastroesophageal reflux in women
    Brian C Jacobson
    Boston University School of Medicine and Boston Medical Center, Boston, USA
    N Engl J Med 354:2340-8. 2006
    ..An association between body-mass index (BMI)--the weight in kilograms divided by the square of the height in meters - and symptoms of gastroesophageal reflux disease in persons of normal weight has not been demonstrated...
  63. ncbi request reprint MIP-3alpha neutralizing monoclonal antibody protects against TNBS-induced colonic injury and inflammation in mice
    Kianoosh Katchar
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston University School of Medicine, Boston, MA 02215, USA
    Am J Physiol Gastrointest Liver Physiol 292:G1263-71. 2007
    ....
  64. ncbi request reprint Toward optimal health: Stefano Guandalini [corrected] M.D., and Ciaran P. Kelly, M.D. Discuss celiac disease. Interview by Jodi R Godfrey
    Stefano Guandalini
    J Womens Health (Larchmt) 14:110-6. 2005
  65. ncbi request reprint Playing host to the difficult Clostridium
    Ciaran P Kelly
    Clin Gastroenterol Hepatol 5:912-4. 2007

Research Grants15

  1. Immune Response to Clostridium difficile
    Ciaran Kelly; Fiscal Year: 2007
    ..difficile associated ileo-cecitis in hamsters. These specific aims are designed to advance further our knowledge of the immunobiology of C. difficile toxin-induced diarrhea and the mechanisms of immune protection in humans. ..
  2. Immune Response to Clostridium difficile
    Ciaran Kelly; Fiscal Year: 2006
    ..difficile associated ileo-cecitis in hamsters. These specific aims are designed to advance further our knowledge of the immunobiology of C. difficile toxin-induced diarrhea and the mechanisms of immune protection in humans. ..
  3. Immune Response to Clostridium difficile
    Ciaran Kelly; Fiscal Year: 2005
    ..difficile associated ileo-cecitis in hamsters. These specific aims are designed to advance further our knowledge of the immunobiology of C. difficile toxin-induced diarrhea and the mechanisms of immune protection in humans. ..
  4. MECHANISMS OF LEUKOCYTE RECRUITMENT IN IBD
    Ciaran Kelly; Fiscal Year: 2005
    ..An in-depth, mechanistic understanding of the regulation of ENA-78 gene expression in human enterocytes may lead to novel therapeutic approaches to IBD. ..
  5. Immune Response to Clostridium difficile
    Ciaran Kelly; Fiscal Year: 2004
    ..difficile associated ileo-cecitis in hamsters. These specific aims are designed to advance further our knowledge of the immunobiology of C. difficile toxin-induced diarrhea and the mechanisms of immune protection in humans. ..
  6. MECHANISMS OF LEUKOCYTE RECRUITMENT IN IBD
    Ciaran Kelly; Fiscal Year: 2004
    ..An in-depth, mechanistic understanding of the regulation of ENA-78 gene expression in human enterocytes may lead to novel therapeutic approaches to IBD. ..
  7. MECHANISMS OF LEUKOCYTE RECRUITMENT IN IBD
    Ciaran Kelly; Fiscal Year: 2003
    ..An in-depth, mechanistic understanding of the regulation of ENA-78 gene expression in human enterocytes may lead to novel therapeutic approaches to IBD. ..
  8. MECHANISMS OF LEUKOCYTE RECRUITMENT IN IBD
    Ciaran Kelly; Fiscal Year: 2002
    ..An in-depth, mechanistic understanding of the regulation of ENA-78 gene expression in human enterocytes may lead to novel therapeutic approaches to IBD. ..
  9. PATHOGENIC MECHANISMS OF HELICOBACTER PYLORI GASTRITIS
    Ciaran Kelly; Fiscal Year: 2002
    ..Identifying H.pylori virulence factors which modulate host immune and inflammatory responses and determining their mechanisms of action are key to targeting new management strategies for this highly prevalent pathogen. ..
  10. PATHOGENIC MECHANISMS OF HELICOBACTER PYLORI GASTRITIS
    Ciaran Kelly; Fiscal Year: 2001
    ..Identifying H.pylori virulence factors which modulate host immune and inflammatory responses and determining their mechanisms of action are key to targeting new management strategies for this highly prevalent pathogen. ..
  11. MECHANISMS OF LEUKOCYTE RECRUITMENT IN IBD
    Ciaran Kelly; Fiscal Year: 2001
    ..An in-depth, mechanistic understanding of the regulation of ENA-78 gene expression in human enterocytes may lead to novel therapeutic approaches to IBD. ..
  12. PATHOGENIC MECHANISMS OF HELICOBACTER PYLORI GASTRITIS
    Ciaran Kelly; Fiscal Year: 2000
    ..Identifying H.pylori virulence factors which modulate host immune and inflammatory responses and determining their mechanisms of action are key to targeting new management strategies for this highly prevalent pathogen. ..
  13. PATHOGENIC MECHANISMS OF HELICOBACTER PYLORI GASTRITIS
    Ciaran Kelly; Fiscal Year: 1999
    ..Identifying H.pylori virulence factors which modulate host immune and inflammatory responses and determining their mechanisms of action are key to targeting new management strategies for this highly prevalent pathogen. ..